Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma

被引：0
|
作者：
S Lee
Y H Park
K H Kim
E Y Cho
Y C Ahn
K Kim
Y-M Shim
J S Ahn
K Park
Y-H Im
机构：
[1] Samsung Medical Center,Division of Hematology
[2] Sungkyunkwan University School of Medicine,Oncology, Department of Medicine
[3] Samsung Medical Center,Department of Pathology
[4] Sungkyunkwan University School of Medicine,Department of Radiation Oncology
[5] Samsung Medical Center,Department of Thoracic Surgery
[6] Sungkyunkwan University School of Medicine,undefined
[7] Samsung Medical Center,undefined
[8] Sungkyunkwan University School of Medicine,undefined
来源：
British Journal of Cancer | 2010年 / 103卷
关键词：
oesophageal cancer; capecitabine; cisplatin; thymidine synthase (TS); thymidine phosphorylase (TP); excesion repair cross-complementation group 1 (ERCC1);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：845 / 851
页数：6
相关论文
共 50 条
  • [31] The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis
    Vesna Bišof
    Matea Zajc Petranović
    Zoran Rakušić
    Kristina Ruža Samardžić
    Antonio Juretić
    European Archives of Oto-Rhino-Laryngology, 2016, 273 : 2305 - 2317
  • [32] A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma
    Shuji Hiramoto
    Ken Kato
    Hirokazu Shoji
    Natsuko Okita
    Atsuo Takashima
    Yoshitaka Honma
    Satoru Iwasa
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Yasuhiro Shimada
    Narikazu Boku
    International Journal of Clinical Oncology, 2018, 23 : 466 - 472
  • [33] A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma
    Hiramoto, Shuji
    Kato, Ken
    Shoji, Hirokazu
    Okita, Natsuko
    Takashima, Atsuo
    Honma, Yoshitaka
    Iwasa, Satoru
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    Boku, Narikazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 466 - 472
  • [34] Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype
    Tseden-Ish, Manaljav
    Choi, Yoo-Duk
    Cho, Hyun-Ju
    Ban, Hee-Jung
    Oh, In-Jae
    Kim, Kyu-Sik
    Song, Sang-Yun
    Na, Kook-Joo
    Ahn, Sung-Ja
    Choi, Song
    Kim, Young-Chul
    RESPIROLOGY, 2012, 17 (01) : 127 - 133
  • [35] Impact of the excision repair cross-complementation group 1 predictive biomarker on toxicity and quality of life in advanced non-small cell lung cancer patients randomized in a large, multicenter, cisplatin-based phase III trial
    Santoni-Rugiu, E.
    Vilmar, A.
    Sorensen, J. B.
    VIRCHOWS ARCHIV, 2010, 457 (02) : 189 - 189
  • [36] Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population
    Qi, Yu-Juan
    Cui, Sen
    Yang, Ying-Zhong
    Han, Jing-Qi
    Cai, Bao-Jia
    Sheng, Cun-Fang
    Ma, Yan
    Wuren, Tana
    Ge, Ri-Li
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2013, 9 (03) : 410 - 415
  • [37] High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients
    Ren, Shengxiang
    Zhou, Songwen
    Zhang, Ling
    Xu, Jianfang
    Lv, Meijun
    Zhang, Jie
    Zhou, Caicun
    Zhang, Jie
    CANCER INVESTIGATION, 2010, 28 (10) : 1078 - 1083
  • [38] Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Lin, Ying-Tao
    Zhou, Chong-Chong
    Xu, Kai
    Zhang, Meng-Die
    Li, Xin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [39] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
    Xu, Jianming
    Kato, Ken
    Raymond, Eric
    Hubner, Richard A.
    Shu, Yongqian
    Pan, Yueyin
    Park, Sook Ryun
    Ping, Lu
    Jiang, Yi
    Zhang, Jingdong
    Wu, Xiaohong
    Yao, Yuanhu
    Shen, Lin
    Kojima, Takashi
    Gotovkin, Evgeny
    Ishihara, Ryu
    Wyrwicz, Lucjan
    Van Cutsem, Eric
    Jimenez-Fonseca, Paula
    Lin, Chen -Yuan
    Wang, Lei
    Shi, Jingwen
    Li, Liyun
    Yoon, Harry H.
    LANCET ONCOLOGY, 2023, 24 (05): : 483 - 495
  • [40] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345